Harvard Medical School’s Longwood Screening facility (ICCB-L) will utilize Cellectricon’s Cellaxess®HT system. According to the company, the system allows for high-throughput transfection enabling reagent-free delivery of genetic material to a wide range of biologically relevant cell types.

“We are excited about the opportunity we have to evaluate Cellaxess HT for genome-wide RNAi delivery to biologically relevant cell types,” says Caroline Shamu, director of ICCB-L.


Previous articleDako to Assist Genentech in Development of a Companion Diagnostic
Next articleInactivation of Specific Protein Halts Prostate Tumor Progression When PTEN Is Lost